Search - tctmd.com

Displaying 121 - 134 of 134

Sort: Relevancy | Date

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

News Daily News

Avoid Simvastatin, Lovastatin in Dabigatran-Treated Patients, Analysis Suggests

November 24, 2016

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

October 18, 2016

News Daily News

Low-Dose NOACs Top Warfarin in Asian Patients in Everyday Practice, Retrospective Study Suggests

September 26, 2016

News Conference News ESC 2016

Edoxaban Shows Safety, Efficacy for A-fib Patients Undergoing Cardioversion: ENSURE-AF

August 30, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Conference News ESC 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

August 27, 2016

News Daily News

ARISTOTLE Analysis: Don’t Shy Away From Standard Apixaban Dose in Certain High-Risk Patients

July 29, 2016

News Daily News

Chinese Patients With A-fib Are at Especially High Risk of Stopping Warfarin

July 08, 2016

News Daily News

Aspirin as Standalone Stroke Protection Still Overused for Patients With A-fib

June 27, 2016

News Daily News

Rivaroxaban May Help Dissolve Left Atrial Thrombus in Patients With A-fib

June 09, 2016

News Conference News ACC 2016

EARLY-BAMI: No Reduction in Infarct Size With IV Metoprolol Before Primary PCI

April 03, 2016

Medical therapy optimization with new anti-ischemic drugs

Presentation JIM 2016

Medical therapy optimization with new anti-ischemic drugs

Presenter: Giuseppe Musumeci

February 11, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.